{"denoms":[{"counts":[{"groupId":"BG000","value":"618"},{"groupId":"BG001","value":"306"},{"groupId":"BG002","value":"924"}],"units":"Participants"}],"groups":[{"description":"Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study.","id":"BG000","title":"9vHPV Vaccine - Base Study"},{"description":"Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study.","id":"BG001","title":"Placebo - Base Study"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"122"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"182"}]}],"title":"12 to 15 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"496"},{"groupId":"BG001","value":"246"},{"groupId":"BG002","value":"742"}]}],"title":"16 to 26 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"618"},{"groupId":"BG001","value":"306"},{"groupId":"BG002","value":"924"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}